文献速递其他结缔组织病

抗拓扑异构酶I IgM抗体与系统性硬化症疾病进展相关

Association of Anti-Topoisomerase I Antibodies of the IgM Isotype With Disease Progression in Anti-Topoisomerase I-Positive Systemic Sclerosis.
PubMed 文献 · Arthritis Rheumatol · 2020-09-29

在莱顿CCISS队列抗拓扑异构酶I IgG阳性系统性硬化症患者中,基线抗拓扑异构酶I IgM阳性者1年内疾病进展比例显著更高(91% vs 57%,P<0.01),并在奥斯陆和苏黎世独立样本中得到验证。

要点

  • 抗拓扑异构酶I IgG阳性患者中,基线IgM阳性与1年疾病进展显著相关。
  • 进展组21/23(91%)为IgM阳性,非进展组33/58(57%)为IgM阳性,P<0.01。
  • 该关联在独立验证样本中得到确认。

核心结论

  • 在抗拓扑异构酶I IgG阳性系统性硬化症患者中,抗拓扑异构酶I IgM阳性与疾病进展相关。

研究设计与样本

  • 莱顿CCISS队列连续血清样本评估基线抗拓扑异构酶I IgG、IgM和IgA水平,1年疾病进展定义包括MRSS增加、肺功能下降、指端溃疡、肾危象、肺动脉高压和/或死亡。
  • 在奥斯陆大学医院和苏黎世大学医院抗拓扑异构酶I阳性患者中进行验证。

主要发现

  • CCISS队列103例抗拓扑异构酶I IgG阳性患者中81例可评估1年疾病进展,其中23例(28%)发生进展。
  • 进展组21/23(91%)基线抗拓扑异构酶I IgM阳性,非进展组33/58(57%)阳性,P<0.01。
  • 该发现在独立验证样本中得到确认。

临床怎么用

  • 对抗拓扑异构酶I IgG阳性系统性硬化症患者,可检测基线抗拓扑异构酶I IgM以辅助识别1年内疾病进展风险较高者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Anti-topoisomerase I (anti-topo I) autoantibodies in systemic sclerosis (SSc) are associated with diffuse skin involvement and interstitial lung fibrosis. Thus far, however, the relationship between anti-topo I antibody response and disease course has not yet been fully evaluated. This study was undertaken to gain insight into the association between characteristics of the anti-topo I antibody response and clinical disease course in SSc patients positive for anti-topo I antibodies. METHODS: Levels of anti-topo I IgG, anti-topo I IgM, and anti-topo I IgA were assessed in consecutive serum samples obtained from patients at baseline who were positive for anti-topo I IgG in the Leiden Combined Care In Systemic Sclerosis (CCISS) cohort. One-year disease progression was defined by a relevant increase in modified Rodnan skin thickness score (MRSS), decline in pulmonary function, development of digital ulcers, renal crisis, and pulmonary hypertension, and/or mortality. Validation was performed in SSc patients who were positive for anti-topo I from the Oslo University Hospital and University Hospital Zurich. RESULTS: Of the 103 patients with anti-topo I IgG in the CCISS cohort, clinical data were available to assess 1-year disease progression in 81 patients. Of these 81 patients, 23 (28%) had disease progression. At baseline, patients with disease progression were significantly more often anti-topo I IgM-positive than those who did not experience disease progression (21 [91%] of 23 versus 33 [57%] of 58; P < 0.01). This finding was confirmed in the independent validation samples. CONCLUSION: In SSc patients who were anti-topo I IgG-positive, presence of anti-topo I IgM, which might be considered as a surrogate for an ongoing autoreactive B cell immune response, is associated with disease progression.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Boonstra M, Bakker JA, Grummels A, et al. Association of Anti-Topoisomerase I Antibodies of the IgM Isotype With Disease Progression in Anti-Topoisomerase I-Positive Systemic Sclerosis. Arthritis Rheumatol. 2020. PMID: 32840062. doi:10.1002/art.41403

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。